brintellex
ValprolBanner
Annals of Indian Academy of Neurology
  Users Online: 2645 Home | About the Journal | InstructionsCurrent Issue | Back IssuesLogin      Print this page Email this page  Small font size Default font size Increase font size
AIAN REVIEW
Year : 2020  |  Volume : 23  |  Issue : 4  |  Page : 458-467

What is new in idiopathic inflammatory myopathies: Mechanisms and therapies


1 Department of Neurology, Bombay Hospital Institute of Medical Sciences, Mumbai, Maharashtra, India
2 Department of Neurology, Dr. L H Hiranandani Hospital, Mumbai, Maharashtra, India

Correspondence Address:
Satish V Khadilkar
Dean, BHIMS and Professor and Head, Department of Neurology, Bombay Hospital Institute of Medical Sciences, Room 110, First Floor, New Wing, Bombay Hospital, 12 New Marine Lines, Mumbai - 400 020, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/aian.AIAN_400_19

Rights and Permissions

Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of disorders that cause muscle weakness and also have extramuscular manifestations involving various organ systems; namely the lung, skin, heart, and joints. Previously classified broadly as dermatomyositis (DM) and polymyositis now the spectrum of the disease has evolved into more clinical subtypes. There are now five clinicoserological subtypes recognized worldwide DM, antisynthetase syndrome (AS), overlap myositis (OM), immune mediated necrotizing myopathy (IMNM), and inclusion body myositis. Each of these subtypes has a unique phenotype and specific antibodies associated. With the evolving treatment options from the use of immunosuppressive medications to the use of targeted therapy with biologic agents, and further understanding of the pathogenesis of inflammatory myositis, we may have more effective treatment options. We discuss in this review, various myositis-associated antibodies associated with each clinicoserological subtype of IIM and their role. We also describe the evolving therapies and the evidence for the newer biologic therapies in the treatment of IIMs.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed400    
    Printed105    
    Emailed0    
    PDF Downloaded154    
    Comments [Add]    

Recommend this journal